Key result
Simulated IKr blockers produce the greatest APD prolongation in LQT1 models, differing across binding formulations.
Why the study?
Most mathematical modelling studies of drug-induced proarrhythmic risk focus on normal conditions and do not account for genetic alterations such as long QT syndromes or natural variability in human cells.
Does the simulation of 12 IKr blockers using dynamic versus static formulations alter action potential duration prolongation in in silico populations of long QT syndrome types 1, 2, and 3 compared to control?
Does the simulation of 12 IKr blockers using dynamic versus static formulations alter action potential duration prolongation in in silico populations of long QT syndrome types 1, 2, and 3 compared to control?
This computational modeling study demonstrates that IKr blockers cause greater action potential duration prolongation in LQT1 models and highlights the necessity of incorporating dynamic drug binding formulations in in silico proarrhythmic risk trials.
Answers are grounded in this paper and cite their sources.
May inform hypotheses on drug effects in long QT syndrome; leaves open clinical validation of static versus dynamic models.
Mathematical modelling of cardiac action potential has become increasingly important for studying drug-induced proarrhythmic risk. However, most studies focus on the effects of compounds under normal conditions and do not consider the influence of genetic alterations, such as long QT syndromes, and the natural variability present in human cells. Here, we evaluate the effects of a series of I Kr blockers on populations of models under control and long QT conditions. Four populations of models were generated and calibrated using experimental data to reproduce the natural variability of the control population and the effects of the three most common forms of long QT syndrome, type 1, 2 and 3. The effect of 12 I Kr blockers on the action potential duration for each population was evaluated using static and dynamic models at different pacing rates. Our models reproduce the fact that long QT syndrome type 2 produces the greater action potential duration prolongation followed by types 3 and 1. Interestingly, the simulated drugs tend to produce longer prolongations in the LQT1 population. Furthermore, using dynamic formulations resulted in statistically significant differences when compared to the use of static models. This study is a step further in the understanding of the interaction between drugs and cardiomyocytes affected by long QT syndromes and lays the groundwork for future in silico trials, while also remarking the importance of considering drug binding dynamics to assess compound effects.
No takes yet. Share an insight, caveat, or question.
Escobar et al. (2026) studied Long QT syndrome (types 1, 2, and 3). 12 IKr blockers using dynamic and static drug formulations vs. Control population models and static vs. dynamic drug formulations was evaluated on Action potential duration prolongation. Simulated IKr blockers across 4 model populations produced the longest action potential duration prolongations in LQT1, with significant differences between dynamic and static formulations.